Clinical Trial Update: Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 study of oxaliplatin with irinotecan in pediatric patients with refractory solid tumors or lymphomas has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Brain Stem Glioma
• Childhood Burkitt Lymphoma
• Childhood Central Nervous System Germ Cell Tumor
• Childhood Cerebellar Astrocytoma
• Childhood Medulloblastoma
• Childhood Neuroblastoma
• Childhood Osteosarcoma
• Childhood Wilms Tumor

Drugs mentioned

• Camptosar (irinotecan)
• Eloxatin (oxaliplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Status: COMPLETED